Efficacy and safety of Abiraterone for patients with metastatic castration- resistant prostate cancer with progression after docetaxel

an evidence

Abstract

Technology: Abiraterone acetate, a drug presented in tablet form, is a potent and irreversible inhibitor of the enzyme that stimulates the synthesis of male hormones (androgens) which are responsible for the growth and evolution of prostate cancer. Indication: Abiraterone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer. Question: Is abiraterone acetate effective and safe for the treatment of patients with metastatic prostate cancer resistant to castration and refractory to chemotherapy? Methods: To answer the PICO question, structured search strategies were used in the following databases: Medline (via Pubmed), Cochrane Library, NICE Evidence Search and Epistemonikos. The methodological quality of the systematic review was evaluated with the AMSTAR tool. Results: Forty publications were identified and, after evaluating full texts, a systematic review article was included in this rapid review. Conclusion: Abiraterone acetate was shown to be effective and safe for the treatment of patients with castration-resistant metastatic prostate adenocarcinoma and refractory to chemotherapy. The available scientific data demonstrated that the drug in question was related to a lower incidence of new tumor lesions, improved quality of life, increased overall survival without significantly increasing the rate of adverse events compared to placebo treatment. The analyzed scientific evidence of high methodological quality supports the incorporation of abiraterone acetate in the institution’s list of standardized drugs.